REGENXBIO cuts 15% workforce, focuses on three lead gene therapies; Q3 net loss $61.9M

REGENXBIO Inc.

Workforce reduction of ~15%, expected $100M cost savings over two years; cash runway extended into H2 2025.
Q3 revenue $28.9M (Zolgensma royalties $28.4M), net loss $61.9M ($1.41/share) vs $75.5M loss year ago.
Lead programs: ABBV-RGX-314 (wet AMD/DR), RGX-202 (Duchenne), RGX-121 (MPS II); strategic alternatives for others.
ABBV-RGX-314 suprachoroidal data: 89% risk reduction in vision-threatening events at one year for dose level 2.
Cash $364.5M as of Sep 30, 2023, down from $565.2M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENXBIO Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.